Study to Assess the Adverse Events, Tolerability, and How Oral Doses of ABBV-932 Moves Through the Body in Healthy Adult Chinese Participants
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Basic science
Enrollment
20actual
Sites
1
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-21 | actual | When the study began enrolling |
| Primary completion | 2025-12-08 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-12-08 | actual | The whole study's end, after follow-up |
| First posted | 2025-06-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteer
Interventions
- Drug: ABBV-932
- Drug: Placebo for ABBV-932
Primary outcomes
what the primary-completion date above is the date OFMaximum Plasma Concentration (Cmax) of ABBV-932
measured Up to approximately 43 days
Time to Cmax (Tmax) of ABBV-932
measured Up to approximately 43 days
Observed plasma concentration at the end of a dosing interval (Ctrough) of ABBV-932
measured Up to approximately 43 days
Area under the plasma concentration-time curve from time 0 until the last measurable concentration (AUCtau) of Desmethyl Cariprazine ABBV-932
measured Up to approximately 43 days
Maximum Plasma Concentration (Cmax) of DCAR
measured Up to approximately 43 days
Time to Cmax (Tmax) of DCAR
measured Up to approximately 43 days
Observed plasma concentration at the end of a dosing interval (Ctrough) of DCAR
measured Up to approximately 43 days
Area under the plasma concentration-time curve from time 0 until the last measurable concentration (AUCtau) of Desmethyl Cariprazine (DCAR)
measured Up to approximately 43 days
Maximum Plasma Concentration (Cmax) of Didesmethyl-Cariprazine (DDCAR)
measured Up to approximately 43 days
Time to Cmax (Tmax) of DDCAR
measured Up to approximately 43 days
Observed plasma concentration at the end of a dosing interval (Ctrough) of DDCAR
measured Up to approximately 43 days
Area under the plasma concentration-time curve from time 0 until the last measurable concentration (AUCtau) of DDCAR
measured Up to approximately 43 days
Number of Participants Experiencing Adverse Events
measured Up to approximately 75 days
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed